Beyond CAR T cells: Engineered Vγ9Vδ2 T cells to fight solid tumors - Archive ouverte HAL Access content directly
Journal Articles Immunological Reviews Year : 2020

Beyond CAR T cells: Engineered Vγ9Vδ2 T cells to fight solid tumors

(1, 2, 3) , (1, 2) , (1, 2)
1
2
3

Abstract

Despite recent significant progress in cancer immunotherapies based on adoptive cell transfer(s)(ACT), the eradication of cancers still represents a major clinical challenge. In particular, the efficacy of current ACT-based therapies against solid tumors is dramatically reduced by physical barriers that prevent tumor infiltration of adoptively transferred effectors, and the tumor environment that suppress their anti-tumor functions. Novel immunotherapeutic strategies are thus needed to circumvent these issues. Human peripheral blood Vγ9Vδ2 T cells, a non-alloreactive innate-like T lymphocyte subset, recently proved to be a promising anti-tumor effector subset for ACT-based immunotherapies. Furthermore, new cell engineering tools that leverage the potential of CRISPR/Cas technology open astounding opportunities to optimize their anti-tumor effector functions. In this review, we present the current ACT strategies based on engineered T cells and their limitations. We then discuss the potential of engineered Vγ9Vδ2 T cell to overcome these limitations and improve ACT-based cancer immunotherapies.
Not file

Dates and versions

inserm-03496227 , version 1 (20-12-2021)

Identifiers

Cite

Chirine Rafia, Christelle Harly, Emmanuel Scotet. Beyond CAR T cells: Engineered Vγ9Vδ2 T cells to fight solid tumors. Immunological Reviews, 2020, 298 (1), pp.117-133. ⟨10.1111/imr.12920⟩. ⟨inserm-03496227⟩
16 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More